Background: Non-communicable diseases (NCDs) represent a leading cause of global mortality, demanding innovative approaches to management. Voice assistants (VAs) have emerged as promising tools in healthcare, offering support for self-management, behavioral engagement, and patient care. This systematic review evaluates the role of VAs in NCD management, analyzing their impact on clinical and behavioral outcomes, quality of life, usability, and user experiences while identifying barriers to their adoption. Methods: A systematic search was conducted in PubMed, Scopus, and Web of Science from January 2014 to October 2024. Studies were selected based on predefined inclusion and exclusion criteria using the PRISMA guidelines. Data extraction focused on outcomes such as usability, acceptability, adherence, clinical metrics, and quality of life. The risk of bias was assessed using the Cochrane Risk of Bias (RoB) 2 and ROBINS-I tools. Results: Eight studies involving 541 participants were included, examining VAs across various NCD contexts such as diabetes, cardiovascular diseases, and mental health. While VAs demonstrated good usability and moderate adherence, their clinical and quality-of-life outcomes were modest. Behavioral improvements, such as increased physical activity and problem-solving skills, were noted in some interventions. Key challenges included privacy concerns, speech recognition errors, and accessibility issues. Conclusions: VAs show potential as supportive tools in NCD management, especially for enhancing patient engagement and self-management, and their impact on clinical outcomes and long-term usability requires further investigation. Future research should focus on diverse populations, standardized metrics, and comparative studies with alternative technologies.

Proteinuria is a strong predictor of graft failure in kidney transplant recipients (KTRs). While non-steroidal mineralocorticoid receptor antagonists (NS-MRAs), particularly finerenone, have demonstrated renoprotective benefits in chronic kidney disease, KTRs were excluded from pivotal trials. Evidence on finerenone’s safety and antiproteinuric effects in this population remains limited. This retrospective observational study evaluated 13 diabetic KTRs with persistent proteinuria despite optimized renin–angiotensin system blockade and sodium–glucose cotransporter 2 inhibitor therapy. Finerenone (10 mg/day) was added to standard care. Clinical and laboratory parameters, including estimated glomerular filtration rate (eGFR), serum electrolytes, total proteinuria, albuminuria, and their creatinine ratios, were assessed at baseline, 3 months, and 6 months. Safety outcomes focused on hyperkalemia and eGFR. Finerenone was discontinued in one patient due to hyperkalemia. In the remaining 12, 24-h proteinuria and urinary protein-to-creatinine ratio declined at 3 months and stabilized by 6 months. Conversely, no statistically significant changes were observed in albuminuria or the albumin-to-creatinine ratio. No clinically relevant changes occurred in eGFR, blood pressure, body weight, or serum electrolytes. This is the first study assessing finerenone in diabetic KTRs. Finerenone was well tolerated, was associated with an early reduction in proteinuria, and showed no adverse effects on graft function. These findings provide novel insights into the safety and potential role of finerenone in kidney transplant recipients.